Neuroscience and Neurochemistry

About us

The 39th International Conference on Neuroscience and Neurochemistry will be held on October 19–20, 2026, in Paris, France, bringing together leading neuroscientists, neurochemists, clinicians, researchers, academicians, and industry innovators from across the globe. Centered on the theme “Rewiring the Future of Brain Science: Global Innovations in Neuroscience and Neurochemistry for Transformative Healthcare,” the conference aims to foster international collaboration and accelerate breakthroughs that translate laboratory discoveries into real-world clinical solutions. As neurological and psychiatric disorders continue to rise worldwide, the need for integrated, multidisciplinary approaches has never been greater. This prestigious global platform will highlight cutting-edge research in molecular neuroscience, neurochemical signaling pathways, neurodegeneration, synaptic plasticity, neuroinflammation, computational neuroscience, and emerging therapeutic technologies. Special focus will be given to precision medicine, biomarker discovery, advanced neuroimaging, brain–computer interfaces, and novel pharmacological strategies that are shaping the next era of brain health. The conference will feature keynote presentations from distinguished experts, plenary sessions, technical workshops, oral and poster presentations, and networking forums designed to encourage meaningful scientific exchange. Participants will gain valuable insights into the latest trends, translational research models, and collaborative opportunities that are redefining modern neuroscience and neurochemistry.

By connecting global thought leaders and fostering dialogue between academia, healthcare institutions, and industry, the 39th International Conference on Neuroscience and Neurochemistry seeks to create lasting impact on research innovation, clinical practice, and public health policy. Join us in Paris for two inspiring days dedicated to advancing brain science and shaping a healthier neurological future for communities worldwide.

Sessions

AI & Machine Learning in Neuroscience Research and Drug Discovery

Artificial intelligence and machine learning are reshaping the landscape of neuroscience by enabling large-scale integration of complex biological and clinical datasets. Modern brain research generates enormous volumes of neuroimaging, electrophysiological, genomic, and behavioral data that traditional analytical methods struggle to interpret. Advanced AI algorithms can detect subtle patterns within these datasets, uncovering previously unrecognized disease mechanisms and predictive biomarkers. Machine learning models enhance diagnostic accuracy in conditions such as Alzheimer’s disease, epilepsy, depression, and Parkinson’s disease by identifying early neural signatures. In drug discovery, AI-driven platforms accelerate compound screening, optimize molecular structures, and predict pharmacokinetics and toxicity profiles, significantly reducing development timelines and costs. Deep learning tools also support patient stratification for clinical trials, increasing trial efficiency and improving therapeutic success rates. Integration of AI with neuroinformatics databases promotes collaborative global research and data reproducibility. Ethical governance, algorithm transparency, and validation across diverse populations remain essential to ensure reliability and equity. The convergence of computational science and neuroscience is creating transformative opportunities for precision medicine, bridging academic research with pharmaceutical innovation, and redefining the future of brain disorder treatment worldwide.

Neurochemical Biomarkers for Early Diagnosis of Neurodegenerative Disorders

Neurochemical biomarkers are revolutionizing the early detection and monitoring of neurodegenerative diseases by identifying molecular changes that precede clinical symptoms. Advances in proteomics, metabolomics, lipidomics, and transcriptomics have enabled the discovery of disease-specific biochemical signatures in blood, cerebrospinal fluid, and even saliva. Biomarkers such as amyloid-beta, tau proteins, alpha-synuclein, and neurofilament light chain are increasingly used to assess disease progression and therapeutic response. Integration of biomarker analysis with advanced neuroimaging and genetic profiling enhances diagnostic precision and allows risk stratification at pre-symptomatic stages. Early identification of pathological processes enables timely intervention, potentially slowing disease progression and improving patient outcomes. Standardization of laboratory assays, multi-center validation studies, and regulatory alignment are critical for clinical implementation. Emerging digital biomarker platforms and wearable monitoring devices further complement molecular diagnostics. Collaboration between academic laboratories, biotechnology companies, and healthcare providers is accelerating translation from research to routine practice. Biomarker-driven strategies are paving the way toward personalized neurology, improving preventive care models, and supporting global efforts to reduce the burden of neurodegenerative disorders.

Precision Neuropharmacology and Targeted Brain Therapeutics

Precision neuropharmacology focuses on tailoring therapeutic interventions based on an individual’s genetic, molecular, and neurochemical profile. Advances in pharmacogenomics allow clinicians to predict drug responses and minimize adverse effects by considering variations in metabolic enzymes and receptor subtypes. High-resolution receptor mapping and ligand-binding studies support the development of highly selective compounds targeting specific neural pathways. Innovative drug delivery technologies, including nanoparticle carriers, liposomal systems, and blood–brain barrier modulation strategies, improve targeted brain penetration and therapeutic efficiency. Biomarker-guided treatment monitoring enables adaptive dosing and dynamic therapeutic adjustments. Precision approaches are particularly impactful in managing epilepsy, mood disorders, schizophrenia, and neurodegenerative diseases. Integration of real-world evidence, digital health tracking, and translational research models accelerates regulatory approval and clinical adoption. Multidisciplinary collaboration among neuroscientists, chemists, pharmacologists, and industry partners strengthens development pipelines. As personalized medicine advances, precision neuropharmacology promises safer, more effective brain therapeutics and improved long-term patient outcomes.

Synaptic Plasticity and Molecular Mechanisms of Memory Formation

Synaptic plasticity forms the biological foundation of learning, memory, and behavioral adaptation. Long-term potentiation and long-term depression involve dynamic changes in synaptic strength regulated by neurotransmitter release, receptor trafficking, intracellular signaling cascades, and gene transcription. Cutting-edge tools such as optogenetics, super-resolution microscopy, and calcium imaging allow real-time visualization of synaptic modifications at molecular resolution. Recent discoveries emphasize the role of glial cells, epigenetic modulation, and structural remodeling in sustaining neural network adaptability. Disruptions in plasticity pathways are linked to cognitive impairment, autism spectrum disorders, and neurodegenerative diseases. Understanding these molecular mechanisms provides insight into therapeutic strategies aimed at enhancing synaptic resilience and restoring cognitive function. Pharmacological agents, neurostimulation techniques, and behavioral interventions are being explored to modulate plasticity in clinical settings. Continued interdisciplinary research is expanding knowledge of how experience reshapes neural circuits, offering transformative implications for education, rehabilitation, and treatment of neurological disorders.

Neuroinflammation and Immune-Brain Interactions

Neuroinflammation represents a critical intersection between the immune system and central nervous system, influencing both neuroprotection and neurodegeneration. Activation of microglia and astrocytes, along with cytokine signaling cascades, contributes to pathological processes in Alzheimer’s disease, multiple sclerosis, traumatic brain injury, and depression. The blood–brain barrier plays a central role in regulating immune cell infiltration and maintaining neural homeostasis. Emerging research highlights bidirectional communication between peripheral immune responses and brain circuits, affecting cognition, mood, and behavior. Advanced molecular profiling techniques are identifying inflammatory biomarkers that predict disease progression and therapeutic response. Novel immunomodulatory therapies aim to reduce harmful inflammation while preserving protective immune functions. Personalized approaches targeting specific inflammatory pathways show promise in clinical trials. Understanding immune-brain dynamics is essential for developing next-generation treatments that balance inflammation control with neural regeneration, ultimately improving long-term neurological outcomes.

Advances in Brain–Computer Interfaces and Neural Engineering

Rapid advancements in brain–computer interfaces (BCIs) and neural engineering are transforming neurorestorative medicine and human–machine integration. High-resolution neural implants, flexible bio-compatible electrodes, and non-invasive stimulation techniques enable direct communication between neural circuits and external devices. These technologies support motor rehabilitation, prosthetic control, communication in paralysis, and treatment-resistant neurological conditions. Artificial intelligence enhances signal decoding accuracy, allowing adaptive and personalized device responses. Innovations in wireless systems and long-lasting biomaterials improve safety and long-term functionality. Integration with robotics and assistive technologies expands applications in clinical and research environments. Ethical considerations, cybersecurity, and equitable access remain critical components of responsible implementation. As interdisciplinary collaboration grows, neural engineering continues to redefine possibilities for restoring lost neurological function and advancing precision neurotechnology worldwide.

CRISPR and Gene Editing in Neurological Disease Treatment

Gene editing technologies, particularly CRISPR-Cas systems, are transforming therapeutic strategies for neurological disorders by enabling precise modification of disease-causing genes. Advances in genome engineering now allow targeted correction of mutations associated with conditions such as Huntington’s disease, spinal muscular atrophy, and certain inherited epilepsies. Improved delivery systems, including viral vectors and lipid nanoparticles, enhance the efficiency and specificity of gene editing within neural tissues. Recent developments focus on minimizing off-target effects, improving editing accuracy, and ensuring long-term safety. Base editing and prime editing technologies further expand the scope of therapeutic possibilities without introducing double-stranded DNA breaks. Ethical oversight, regulatory frameworks, and long-term monitoring remain critical components of responsible clinical translation. Collaborative efforts between molecular biologists, neuroscientists, and biotechnology industries are accelerating progress toward gene-based neurological therapies. As precision medicine advances, gene editing holds immense promise for addressing previously untreatable brain disorders and reshaping the future of neurotherapeutics.

Neurotransmitter Signaling Pathways and Psychiatric Disorders

Neurotransmitter signaling pathways play a central role in regulating mood, cognition, and behavior. Dysregulation of dopamine, serotonin, glutamate, and GABA systems has been strongly linked to psychiatric conditions such as depression, schizophrenia, bipolar disorder, and anxiety disorders. Advances in receptor pharmacology, synaptic transmission studies, and intracellular signaling analysis are providing deeper insight into complex neurochemical imbalances. Modern imaging techniques and molecular profiling enable real-time assessment of neurotransmitter dynamics in both experimental and clinical settings. Emerging therapeutic strategies focus on receptor subtype selectivity, modulation of synaptic plasticity, and personalized pharmacological interventions. Integration of neurochemical research with genetics and environmental studies enhances understanding of multifactorial psychiatric disorders. Continued innovation in this field is critical for developing safer, more effective treatments and improving mental health outcomes worldwide.

Mitochondrial Dysfunction and Metabolic Regulation in Brain Health

Mitochondria are essential for neuronal energy production, calcium homeostasis, and regulation of oxidative stress. Dysfunction in mitochondrial pathways contributes to neurodegenerative diseases, cognitive decline, and metabolic brain disorders. Research advances highlight the impact of impaired oxidative phosphorylation, increased reactive oxygen species, and disrupted metabolic signaling on neuronal survival. Emerging studies explore metabolic therapies, antioxidant strategies, and mitochondrial-targeted compounds aimed at restoring cellular energy balance. Advanced metabolomics and imaging technologies enable precise assessment of brain energy dynamics. Understanding the interplay between metabolic health and neural function opens new avenues for preventive and therapeutic interventions. Targeting mitochondrial pathways represents a promising strategy for maintaining brain resilience and delaying neurodegenerative progression.

Translational Neuroscience: From Bench to Bedside

Translational neuroscience bridges fundamental research discoveries with clinical application to improve patient care. Advances in molecular biology, neuroimaging, and computational modeling are accelerating the transformation of laboratory findings into therapeutic innovations. Robust preclinical models, biomarker validation, and adaptive clinical trial designs strengthen the pathway from discovery to treatment implementation. Collaborative networks among academic institutions, hospitals, and industry partners facilitate knowledge exchange and accelerate regulatory approval processes. Emphasis on reproducibility, real-world evidence, and patient-centered outcomes ensures meaningful clinical impact. By integrating multidisciplinary expertise, translational neuroscience fosters rapid innovation and enhances the global standard of neurological care.

Neurochemistry of Aging and Longevity Science

The neurochemistry of aging explores molecular and cellular changes that influence cognitive decline and longevity. Alterations in neurotransmitter balance, oxidative stress, protein aggregation, and synaptic integrity contribute to age-related neural vulnerability. Research into neuroprotective pathways, including autophagy regulation and anti-inflammatory mechanisms, offers insight into promoting healthy brain aging. Longevity science integrates genetics, lifestyle factors, and metabolic regulation to understand resilience against neurodegeneration. Emerging interventions such as caloric restriction mimetics, senolytic therapies, and neuroprotective compounds aim to enhance cognitive lifespan. Continued investigation into aging-related neurochemical processes supports development of preventive strategies and improved quality of life in aging populations.

Nanotechnology and Targeted Drug Delivery to the Brain

Nanotechnology is revolutionizing targeted drug delivery by overcoming the challenges posed by the blood–brain barrier. Engineered nanoparticles, liposomes, dendrimers, and polymer-based carriers enable controlled release and site-specific targeting of therapeutic agents. These technologies improve bioavailability, reduce systemic toxicity, and enhance treatment precision for neurological disorders. Functionalized nanocarriers can be designed to respond to specific molecular signals within diseased brain regions. Integration with imaging modalities supports theranostic applications, combining diagnosis and therapy in a single platform. Ongoing research emphasizes safety evaluation, long-term stability, and scalable production methods. Nanomedicine represents a transformative approach to delivering next-generation neurotherapeutics effectively and safely.

Stem Cells and Regenerative Neurobiology

Stem cell research is advancing regenerative strategies for repairing damaged neural tissue. Neural stem cells, induced pluripotent stem cells, and mesenchymal stem cells offer potential for replacing lost neurons and restoring functional neural circuits. Advances in cell differentiation protocols, tissue engineering, and biomaterial scaffolds enhance survival and integration of transplanted cells. Regenerative neurobiology also explores endogenous repair mechanisms, neurogenesis stimulation, and growth factor modulation. Preclinical and early-phase clinical trials demonstrate encouraging outcomes in spinal cord injury, stroke, and neurodegenerative disorders. Ethical considerations, immune compatibility, and long-term safety remain essential factors in clinical translation. Stem cell-based therapies hold significant promise for restoring neurological function and redefining treatment paradigms in brain health.

Advanced Neuroimaging and Molecular Brain Mapping

Advanced neuroimaging technologies are transforming understanding of brain structure and function at unprecedented resolution. High-field MRI, functional MRI, PET imaging, diffusion tensor imaging, and magnetoencephalography enable detailed visualization of neural connectivity, metabolic activity, and molecular signaling. Integration of multimodal imaging techniques provides comprehensive mapping of neural circuits involved in cognition, emotion, and behavior. Molecular brain mapping combines imaging with genomics, proteomics, and transcriptomics to identify region-specific cellular and biochemical signatures. These approaches enhance early diagnosis of neurological disorders, improve surgical planning, and support precision therapeutic targeting. Real-time imaging of disease progression allows monitoring of treatment response and biomarker validation. Artificial intelligence further enhances image interpretation and pattern recognition. Continued innovation in imaging resolution, contrast agents, and computational integration is expanding research and clinical capabilities, shaping the future of personalized neuroscience and improving patient-centered neurological care.

Neurotoxicology and Environmental Impacts on Brain Function

Neurotoxicology investigates how environmental toxins, chemicals, heavy metals, and pollutants affect brain development and function. Exposure to substances such as lead, pesticides, air pollutants, and industrial chemicals has been linked to cognitive impairment, neurodevelopmental disorders, and neurodegenerative diseases. Advances in molecular toxicology reveal how toxic agents disrupt neurotransmitter systems, induce oxidative stress, and impair synaptic plasticity. Emerging research emphasizes gene–environment interactions and susceptibility factors influencing neurological outcomes. Biomonitoring technologies and advanced cellular models enable early detection of neurotoxic effects. Preventive public health strategies, regulatory policies, and environmental risk assessments play critical roles in reducing exposure. Understanding environmental impacts on brain health supports evidence-based interventions and global initiatives aimed at protecting vulnerable populations and promoting sustainable neurological well-being.

Digital Therapeutics and Virtual Neuro-Rehabilitation

Digital therapeutics are reshaping neurological treatment through software-based interventions and technology-driven rehabilitation programs. Virtual reality platforms, mobile health applications, wearable sensors, and AI-guided cognitive training programs provide personalized therapeutic experiences. These tools enhance neuroplasticity, improve motor recovery, and support behavioral therapy in conditions such as stroke, Parkinson’s disease, and traumatic brain injury. Remote monitoring and tele-rehabilitation expand accessibility, particularly in underserved regions. Data-driven feedback systems allow adaptive therapy adjustments and measurable outcome tracking. Integration with conventional clinical care improves adherence and long-term functional outcomes. Regulatory validation and clinical evidence continue to strengthen credibility of digital interventions. As technology evolves, digital therapeutics are becoming integral components of modern neurorehabilitation and precision healthcare delivery.

Epigenetics and Brain Plasticity

Epigenetic mechanisms play a crucial role in regulating gene expression without altering DNA sequences. DNA methylation, histone modification, and non-coding RNAs influence neural development, synaptic plasticity, and memory formation. Environmental factors such as stress, nutrition, and learning experiences can induce epigenetic changes that shape long-term brain function. Disruptions in epigenetic regulation are associated with neurodevelopmental disorders, psychiatric conditions, and neurodegenerative diseases. Advances in epigenomic profiling and single-cell analysis provide insight into dynamic gene regulation within neural circuits. Therapeutic approaches targeting epigenetic pathways are emerging as potential strategies to enhance plasticity and cognitive resilience. Continued research into epigenetic modulation offers transformative implications for personalized neuroscience and long-term brain health.

Neurochemical Basis of Addiction and Substance Use Disorders

Addiction involves complex neurochemical alterations within reward, motivation, and stress pathways. Dysregulation of dopamine, glutamate, and opioid systems contributes to compulsive substance-seeking behavior and relapse vulnerability. Chronic exposure to addictive substances induces long-lasting changes in synaptic plasticity and neural circuitry. Advances in molecular neuroscience reveal how genetic predisposition, environmental stressors, and neurochemical imbalances interact to influence addiction risk. Novel pharmacotherapies aim to normalize neurotransmitter function and reduce craving. Behavioral interventions combined with neurobiological insights support comprehensive treatment models. Understanding the neurochemical mechanisms underlying addiction enhances prevention strategies and improves therapeutic outcomes.

Computational Neuroscience and Brain Network Modeling

Computational neuroscience applies mathematical modeling and data-driven simulation to understand complex neural systems. Brain network modeling integrates structural and functional connectivity data to map large-scale neural dynamics. Advanced algorithms simulate synaptic interactions, neural oscillations, and information processing across distributed circuits. These models improve interpretation of neuroimaging data, predict disease progression, and support personalized treatment planning. High-performance computing and AI integration enhance model accuracy and scalability. Collaboration between neuroscientists, physicists, and data scientists drives innovation in brain network research. Computational approaches are essential for decoding complex brain functions and translating theoretical insights into practical clinical applications.

Global Collaborations in Neuroscience Innovation and Industry Partnerships

Global collaboration is essential for accelerating innovation in neuroscience and neurochemistry. International research networks promote data sharing, cross-disciplinary expertise, and multi-center clinical trials. Partnerships between academia, healthcare institutions, biotechnology firms, and pharmaceutical industries facilitate rapid translation of discoveries into therapeutic solutions. Collaborative frameworks strengthen funding opportunities, harmonize regulatory standards, and support technology transfer. Emphasis on diversity, inclusion, and equitable access ensures broad representation in research and clinical advancement. By fostering international cooperation and industry engagement, global partnerships drive sustainable progress and transformative impact in brain science worldwide.

Market Analysis

The Neuroscience and Neurochemistry market is experiencing robust growth driven by expanding global demand for advanced neurological care, rising prevalence of neurological and psychiatric disorders, and accelerated investment in research, diagnostics, and therapeutics. With the global population aging and lifestyle factors such as stress, environmental exposure, and metabolic disorders contributing to increased incidence of Alzheimer’s disease, Parkinson’s disease, epilepsy, stroke, depression, and other brain-related conditions, healthcare systems worldwide are prioritizing neuroscience innovation to meet complex clinical needs. This has resulted in heightened spending on diagnostic technologies, therapeutic drugs, biomarker research, neurotechnology devices, and integrated care solutions, creating a dynamic and multi-faceted market landscape. Neurochemical research is central to understanding brain function at the molecular and cellular levels. Techniques such as proteomics, metabolomics, and advanced molecular imaging have revolutionized the identification of biomarkers associated with neurodegenerative processes, synaptic dysfunction, and psychiatric disorders. These advances are not only improving early diagnosis but also facilitating personalized medicine approaches, whereby treatments are tailored according to individual neurochemical and genetic profiles. The growing emphasis on precision neuroscience has prompted significant funding from government agencies, academic institutions, and private industry to accelerate biomarker discovery, drug development, and clinical translation. Pharmaceutical research remains one of the most active sectors within the neuroscience market, with a strong focus on developing next-generation psychopharmacological agents, neuromodulators, and neuroprotective compounds. Precision neuropharmacology, supported by pharmacogenomic insights, is enabling more effective and safer treatments for conditions that have historically been difficult to manage. Additionally, biologics, small molecules targeting disease-specific pathways, and repurposed drugs with enhanced delivery mechanisms are gaining traction. Strategic collaborations between biotech firms and large pharmaceutical companies are accelerating clinical trial pipelines and expanding therapeutic portfolios. Technology-driven solutions are playing an increasingly significant role. Neurostimulation devices such as transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and emerging non-invasive modalities offer alternatives for treatment-resistant conditions. Brain–computer interfaces (BCIs) and neural engineering innovations are rapidly advancing, offering promising applications for motor rehabilitation, communication restoration, and assistive technologies for patients with severe neurological impairments. Industry investment in wearable and implantable neurotechnology, integrated with artificial intelligence for real-time signal processing and adaptive therapy control, is contributing to commercial expansion. Digital health platforms, including tele-neurology and digital therapeutics, are reshaping care delivery models by enhancing access, continuity, and patient engagement. Telehealth adoption was catalyzed by the COVID-19 pandemic and has since become embedded in standard neurological care, particularly for follow-up consultations, remote monitoring, and cognitive therapy. Digital tools that collect behavioral, physiological, and cognitive performance data support predictive analytics, risk stratification, and personalized treatment adjustments. Despite substantial progress, challenges remain. High costs associated with advanced neurotechnology and specialized treatments pose barriers for access, particularly in low- and middle-income regions. Regulatory complexities, long development timelines, and the scientific challenges of translating preclinical findings into effective clinical therapies necessitate sustained investment and innovative trial designs. Workforce shortages in neurology, neuropsychology, and specialized neurochemistry research also impact service delivery capabilities.

Past Conference Report

Neuroscience 2025

The 38th International Conference on Neuroscience and Neurochemistry, set to take place on November 13-14, 2025, in Paris, France, will serve as a premier platform for leading experts, researchers, clinicians, and industry professionals to explore the latest advancements in neuroscience and neurochemistry. The conference aims to foster discussions on cutting-edge research, innovative therapeutic strategies, and ground-breaking developments in the diagnosis, treatment, and management of neurological disorders. With a diverse and multidisciplinary approach, this event will provide an invaluable opportunity for networking, knowledge sharing, and collaboration in the field of brain science. Neuroscience and neurochemistry play a pivotal role in understanding the intricate workings of the brain, neuronal functions, and the chemical processes that underlie cognition, behaviour, and neurological diseases. The 38th International Conference on Neuroscience and Neurochemistry will focus on a wide array of topics, including neurodegenerative diseases, neuroplasticity, molecular and cellular neuroscience, synaptic transmission, neuroimaging techniques, neuropharmacology, and novel therapeutic approaches. The conference will feature keynote lectures, plenary sessions, interactive workshops, and panel discussions, offering a comprehensive learning experience to all attendees. One of the major objectives of this conference is to address the rising global burden of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, stroke, and neurodevelopmental disorders. The increasing prevalence of these conditions has underscored the need for further research into the molecular mechanisms and biochemical pathways involved in neurodegeneration and neuroprotection. Through this event, experts will present the latest scientific findings and clinical trials, providing insights into potential breakthroughs in treating these disorders.A key highlight of the conference will be its focus on neurotransmitters, synaptic function, and neurochemical signaling pathways that govern brain activity.